Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Brandon K Sack
Malaria Vaccines: Recent Advances and New Horizons
Data sources for this figure included the WHO Malaria Vaccine Rainbow Table and Clinicaltrials.gov . Vaccines for P. vivax are colored blue. The life cycle figure was adapted from Modern malaria vaccine development began with seminal studies in mice using irradiated sporozoites ().
A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein
We would like to thank M. Nussenzweig (Rockefeller University) and H. Wardemann (German Cancer Research Center) for providing reagents for antibody cloning and expression. This work was supported in part by the Swiss Vaccine Research Institute, by the European Research Council (grant no. 670955 BROADimmune) and by the Fondazione Aldo e Cele Daccò. J.T. is funded by the Wellcome Trust (grant no. 204689/Z/16/Z). B.S. is funded by the National Institutes of Health (grant no. F32 AI 114113).
Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects
A triple punch knocks out the malaria parasite Vaccination with weakened infectious forms of the malaria parasite is the most promising approach to protect against malaria infection. However, creating genetically defined and weakened parasite strains that are safe for vaccination remains challenging. In a new study, Kublin et al.
An expanding toolkit for preclinical pre-erythrocytic malaria vaccine development: bridging traditional mouse malaria models and human trials
An expanding toolkit for preclinical pre-erythrocytic malaria vaccine development: bridging traditional mouse malaria models and human trials Malaria remains a significant public health burden with 214 million new infections and over 400,000 deaths in 2015. Elucidating relevant Plasmodium parasite biology can lead to the identification of novel ways to control and ultimately eliminate the parasite within geographic areas.
Characterization of the type I IFN response to liver stage infection with genetically attenuated malaria parasite vaccines.
Malaria, a disease caused by Plasmodium parasites, kills nearly 600,000 people annually. Inoculated by an infectious mosquito bite, Plasmodium sporozoites travel to the liver and infect hepatocytes. Here, they develop into merozoites that are released into the blood to cause malaria associated mortality and morbidity. No fully protective malaria vaccine exists, but immunizations with genetically attenuated parasites (GAPs) that arrest in the liver confer sterile protection from challenge in mice.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Brandon K
Contact Brandon K, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack